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A recent report suggests that the KLF6 gene encoding the Kru ¨ppel-like factor 6 protein is a frequently mutated, putative tumour
suppressor gene in prostate cancer. The aims of the present study were to confirm these initial findings by determining the frequency
of exon2 KLF6 mutations in a cohort of European prostate cancer patients, and to investigate whether there was evidence for
mutational inactivation of both the KLF6 and TP53 tumour suppressor loci in some tumours. We examined 32 primary prostate
tumours and three prostate tumour cell lines for mutations by PCR amplification and direct dideoxy sequencing (KLF6), and by
oligonucleotide microarray (p53GeneChipt) analysis and dideoxy sequencing (TP53). Whereas TP53 mutations typical of prostate
cancer were found at a frequency consistent with the literature, no KLF6 mutations were found in any of the tumour samples nor in
the three prostate cancer cell lines.
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Kru ¨ppel-like factors serve as core transcription factors and
participate in regulation of numerous mammalian genes (Bieker,
2001; Black et al, 2001). One of the factors, KLF6, is thought to play
a role in repair of vascular injury and in tissue remodelling
(Kojima et al, 2000). Very recent findings have suggested that the
KLF6 protein also shares several intriguing features in common
with the TP53 tumour suppressor protein. Their tumour
suppressor properties rely at least in part on the ability to regulate
transcription of growth control genes, and loss of function in
neoplastic development typically occurs when a missense mutation
arises in one allele, and the remaining allele is lost (Hainaut and
Hollstein, 2000; Vogelstein et al, 2000; Narla et al, 2001). In
addition, the two proteins have in common at least one important
transcriptional target, WAF1/p21, an inhibitor of cyclin-dependent
kinases and regulator of cellular growth arrest. In prostate cancer,
inactivating TP53 mutations are detected at frequencies in the
range of 10–20% in primary tumours (IARC TP53 Mutation
Database: www.iarc.fr/P53/index.html1), whereas based on the
novel findings of Narla et al (2001), tumour-specific KLF6
mutations would be expected overall in up to half of sporadic
prostate tumours with Gleason scores in the range of 3–8 (not
preselected for loss of heterozygosity status), and thus would
constitute the most frequent gene mutation event identified to date
in prostate carcinogenesis. If mutations that compromise function
of the KLF6 transcription factor are indeed common in prostate
cancer, we might then ask whether clustering analysis of data from
molecular profiling of tumours (Ernst et al, 2002) would define
KLF6 mutant tumours as a subgroup.
METHODS
We examined tumour material from 32 patients from Germany,
most of whom had disease with a Gleason score of 7 or higher
(Table 1). Tumour areas with 490% neoplastic cellularity were
either microdissected from 5mm tissue sections cut from buffered
formalin-fixed paraffin-embedded material, or tumour cells were
catapulted from sections of snap-frozen tumour tissue with a
P.A.L.M. laser device (P.A.L.M. Microlaser Technologies, Bernried,
Germany) as indicated in Table 1. To avoid the hazards of
polymerase chain reaction (PCR) contamination, genomic DNA
was extracted in a laboratory designed for that purpose in which
neither PCR reactions are performed nor PCR products handled.
Polymerase chain reaction set-up was performed in a second
laboratory in a special hood equipped with UV lamps that were
illuminated for 30min before the beginning of each PCR
experiment. Exon 2 of the KLF6 gene (the exon with the longest
coding sequence and in which all but two KLF6 mutations were
reported previously) was amplified with primers we designed to
optimise amplification (KLF6Ex2F and KLF6Ex2R, Table 2).
Reactions were performed in 1  PCR buffer from Boehringer
Mannheim (final concentration of MgCl2: 1.5mM), 200mM dNTPs,
and 2.5U Taq polymerase (Boehringer Mannheim, Germany) in a
total volume of 50ml. Amplification was performed in an MJB
thermal cycler programmed for 40 cycles (951C, 1min; 601C, 1min;
721C 1min), and included an initial denaturation step at 951C for
2min, and a final elongation step of 5min at 721C. Polymerase
chain reaction products were purified with Microcon 100 filters Received 6 February 2003; revised 16 May 2003; accepted 27 May 2003
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dideoxy cycle sequencing reactions with fluorescent dye-labelled
dideoxynucleotides and DNA polymerase from Applied Biosys-
tems International (ABI, Weiterstadt, Germany). Four cycle
sequencing reactions were performed, using primers KLF6Ex2FC,
KLF6Ex2RC, KLF6Ex2R and KLF6Ex2FA (Table 2), which allowed
accurate reading of both DNA strands of all of exon 2 (571bp) and
adjacent splice sites. For 28 of the 32 tumours, there was sufficient
material to allow two independent amplification reactions of exon
2 from genomic DNA, and sequencing of the entire fragment in
both directions. Capillary electrophoresis of sequencing reaction
products was performed with the ABI Model 310 Genetic Analyzer.
TP53 mutation analysis was performed on tumours from 25 of
the patients, using aliquots of the same genomic DNA samples that
were tested for KLF6 mutations, but employing reagents for
multiplex PCR of the TP53 gene. Reagents and p53GeneChips were
purchased from Affymetrix (Santa Clara, CA, USA) and used
according to recommendations from the manufacturer. Chips were
scanned with a Hewlett-Packard GeneArray scanner and signal
intensities were evaluated with Affymetrix GeneChip software. The
probe array methodology scans all coding exons and splice sites of
the human p53 gene for point mutations with high efficiency and
accuracy (Ahrendt et al, 1999; Wen et al, 2000). To confirm results,
tumours screened with the p53GeneChip that yielded mutant
Table 1 KLF6 and TP53 gene mutation analysis of prostate tumours from European patients
Mutation analysis results
Patient Age (years) Tumour classification Grading Gleason score Tumour cell recovery KLF6 (ddSeq) TP53 (Array) TP53 (ddSeq)
#1 78 pT3a, pN0, pMx G2 7 Microdissection Neg. Neg.
#2 78 (not classifiable) G3 9 Microdissection Neg. c.190 CCT/CTT c.190 CCT/CTT
#3 64 pT2b, pNx, pMx G2 6 Microdissection Neg. ND
#4 73 pT3b, pN1, pMx G3 9 Microdissection Neg. ND
#5 83 pT1b, pN0, pMx G2–G3 7 Microdissection Neg. Neg.
#6 73 pT3a, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#7 65 pT2b, pN0, pMx G1–G2 5 Microdissection Neg. Neg.
#8 70 pT3a, pN0, pMx G2 6 Microdissection Neg. Neg.
#9 73 pT2, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#10 72 pT2a, pN0, pMx G2 7 Microdissection Neg. Neg.
#11 63 pT2b, pNx, pMx G2 7 Laser capture Neg. ND
#12 77 pT3a, pN0, pMx G2 7 Laser capture Neg. ND
#13 64 pT4, pN0, pMx G3 9 Laser capture Neg. ND
#14 71 pT3b, pN0, pMx G2 7 Laser capture Neg. Neg.
#15 64 pT3b, pN1, pMx G3 9 Laser capture Neg. ND
#16 62 pT3, pN0, pMx G2 7 Laser capture Neg. ND
#17 71 pT2b, pN0, pMx G2–G3 7 Microdissection Neg. Neg.
#18 75 pT2a, pN0, pMx G1 4 Microdissection Neg. c.285 GAG/AAG c.285 GAG/AAG
#19 65 pT3a, pN0, pMx G2–G3 7 Microdissection Neg. Neg.
#20 71 pT3b, pN0, pMx G2–G3 7 Microdissection Neg. Neg.
#21 61 pT3a, pN0, pMx G2–G3 6 Microdissection Neg. Neg.
#22 73 pT2b, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#23 64 pT3a, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#24 72 pT3b, pN0, pMx G1–G3 8 Microdissection Neg. Neg.
#25 70 pT3a, pN0, pMx G2 6 Microdissection Neg. Neg.
#26 66 pT3b, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#27 59 pT2b, pN0, pMx G2–G3 8 Microdissection Neg. Neg.
#28 66 pT2b, pN0, pMx G2 7 Microdissection Neg. Neg.
#29 67 pT3a, pN1, pMx G2–G3 8 Microdissection Neg. c.282 CGG/TGG c.282 CGG/TGG
#30 66 pT3b, pN1, pMx G2–G3 8 Microdissection Neg. Neg.
#31 66 pT3b, pN1, pMx G2–G3 8 Microdissection Neg. Neg.
#32 64 pT3b, pN1, pMx G3 9 Microdissection Neg. Neg.
ddSeq¼Sanger dideoxy sequencing; Array¼Affymetrix P53 GeneChip; Neg.¼negative; ND¼not done.
Table 2 Primers used in this study
Name Gene Sequence
KLF6Ex2F KLF6 50 CGGGCAGCAATGTTATCTGTCCTTC 30
KLF6Ex2FA KLF6 50 TCGTCATGGCAATCACGTGCCTTC 30
KLF6Ex2R KLF6 50 CGGCTCCCTCCAGGGCTGGTGCA 30
KLF6Ex2FC KLF6 50 CCCACGGCCAAGTTTACCTCCGACC 30
KLF6Ex2RC KLF6 50 GGAGCTCAATTTTCCCGAGCTGACC 30
GCEx8F TP53 50 GTAGGACCTGATTTCCTTACTGCCTCTTGC 30
GCEx8R TP53 50 ATAACTGCACCCTTGGTCTCCTCCACCGC 30
GCEx5F TP53 50 CTTGTGCCCTGACTTTCAACTCTGTCTC 30
GCEx5R TP53 50 TGGGCAACCAGCCCTGTCGTCTCTCCA 30
GCEx6F TP53 50 CCAGGCCTCTGATTCCTCACTGATTGCTC 30
GCEx6R TP53 50 GCCACTGACAACCACCCTTAACCCCTC 30
Multiplex PCR for P53GeneChip analysis was performed with the P53 Primer Set from Affymetrix.
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used above for KLF6, that is, PCR amplification of individual exons
from genomic DNA using primers listed in Table 2, and dideoxy
cycle sequencing, as we have described previously for the TP53
gene (Biramijamal et al, 2001).
RESULTS AND DISCUSSION
We did not find mutations in exon 2 of the KLF6 gene in any of the
32 tumour samples that we examined (Table 1) nor in the human
prostate tumour cell lines PC-3, DU-145 and LNCaP. The
P53GeneChipt protocol identified TP53 gene mutations in three
of the 25 tumours (12%). All were transitions at G:C base pairs
(the most common type of mutation in this cancer type) at codons
previously reported mutated in prostate and other cancers (Olivier
et al, 2002). The presence of these mutations was confirmed by
amplifying genomic DNA with p53-specific primers, and then
performing cycle sequencing and electrophoretic analysis follow-
ing the same standard methodology used for KLF6 analysis
(Table 1, Figure 1).
Results of the TP53 mutation analysis were as expected
from data in the scientific literature; however, the absence of
KLF6 miscoding mutations in our patients and in the three
human prostate cancer cell lines was unexpected. If KLF6
mutations were a common event in primary prostate cancer,
it is likely that most tumour cell lines would harbour KLF6
mutations, because tumour cell lines typically harbour specific
oncogene or tumour suppressor gene mutations at still higher
prevalence than the frequencies detected in the corresponding
primary tumours, and analysis is not plagued by particular
technical difficulties such as contamination of tumour cells with
non-neoplastic tissue.
Our findings on 32 European patients with prostate cancer
(average Gleason score 7.3) suggest that KLF6 miscoding muta-
tions in tumours of the prostate are uncommon. While the present
report was under initial review, a new study on KLF6 alterations in
prostate tumours appeared in the American Journal of Pathology
reporting a low prevalence of miscoding KLF6 mutations in
tumours of patients with high-grade prostate cancer (9%, average
Gleason score 48, 75 tumours analysed; Chen et al, 2003). None of
the mutations found by Chen et al occurred in the zinc-finger
domains of KLF6, and none was identical to the mutations
discovered by Narla et al. Thus, both the findings of Chen et al and
our results contrast with the data in the first study (Narla et al,
2001), which suggested that KLF6 mutations are a common feature
of prostate cancer (55%, 19 out of 34 tumour samples, average
Gleason score 6.3). On the basis of information in these three
studies, it is not likely that the discrepancies are attributable to
differences in tumour grade of sample sets, whereas patient
ethnicity (not given in the publications cited) and details of
mutation analysis protocols merit attention in further investiga-
tions on the role of KLF6 mutations in prostate cancer.
Additional studies are called for in order to clarify whether
KLF6 is indeed a common mutational target in prostate car-
cinogenesis.
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Figure 1 TP53 analysis of tumour 2 by P53GeneChipt and by Sanger
dideoxy sequencing. (A) Bar chart shows signal intensities from array tiling
that screened codon 190 from a P53GeneChip hybridised with target from
tumour 2. The C to T transition at codon 190 is indicated by the bar at
position 2 [C C Tt oCT/C T, Proline (P) to Leucine (L)]. (B)
Electropherogram from ABI Genetic Analyzer showing p53 exon 6 DNA
sequence (50 to 30) in tumour 2. The ‘N’ shows the position of the C to T
transition at the second position of codon 190.
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